

<b>Customer Name</b>	Arçelik
<b>Customer Address</b>	Çayirova Campus, Tuzla, 34950 Istanbul, Turkey
<b>Contact</b>	Fatih Kasap
<b>Test Requested</b>	Assessment of effect of test device on bacterial and viral viability
<b>Sample Description</b>	UV-C Disinfection Unit BEKO UVT 5033 TA / 7730430201
<b>Number of Samples</b>	1
<b>Date of Receipt</b>	24 July 2020
<b>ASC Code</b>	ASC003963
<b>Report Number</b>	ASCR092442
<b>Report Date</b>	21 January 2021

## 1. Purpose

This report outlines the results of the study performed to assess the ability of the:

- UV-C Disinfection Unit (BEKO UVT 5033 TA)
  - UV-C and heat-assisted disinfection program for 40 minutes UV Cleaning to remove bacteria and virus.

## 2. Test Item Description

The UV-C Disinfection Unit (BEKO UVT 5033 TA) was submitted to airmid healthgroup on 24<sup>th</sup> July 2020 (Figure 2.1).



**Figure 2.1.** UV-C Disinfection Unit

### 3. Materials

---

#### 3.1. ***Staphylococcus aureus* subsp. *aureus* Rosenbach (ATCC® 6538™)**

*S. aureus* is a Gram-positive, round-shaped bacterium that is a common member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin.

#### 3.2. ***Escherichia coli* (Migula) Castellani and Chalmers (ATCC® 8739™)**

*E. coli* is a Gram-negative, facultative anaerobic, rod-shaped, coliform bacterium commonly found in the lower intestine of warm-blooded organisms.

#### 3.3. **Human Coronavirus 229E (ATCC® VR-740™)**

Coronaviruses were first discovered in the 1960's, causing upper respiratory tract infections in healthy individuals and serious disease in patients with comorbidities. Pathogenic human coronaviruses (HCoV) were subsequently identified, beginning with the discovery of SARS-CoV in 2002 and the recent detection of SARS-CoV-2. There are now seven identified human coronaviruses, those causing mild disease (229E, OC43, NL63, HKU1) and those causing severe respiratory illness (SARS-CoV, MERS, SARS-CoV-2). HCoV-229E was the chosen model for this project as it is a biosafety level 2 pathogen with similar genetic and protein composition to the SARS-CoV-2 virus.

## 6. Conclusion

---

The UV-C Disinfection Unit (BEKO UVT 5033 TA), UV-C and heat-assisted disinfection program for 40 minutes was demonstrated to be effective in reducing the tested bacteria and virus, achieving 99.99 % reduction against *S. aureus*, 99.99 % reduction against *E. coli*, and 99.97% reduction against Human coronavirus 229E. HCoV-229E was the chosen model for this project as it is a biosafety level 2 pathogen with similar genetic and protein composition to the SARS-CoV-2 virus.

## 7. Additional Products

---

According to the Declaration of Conformity signed by Arçelik (dated 19.11.20) the products listed below conform in all aspects relating to performance in testing parameters to the UV-C Disinfection Unit (BEKO UVT 5033 TA / 7730430201)

- Beko / 7730430201 / UVT 5033 TA
- Arçelik / 7730420101 / UVT 6033 TA
- Beko / 7730430202 / UVT 5033 TA
- Voltas Beko / 7730430203 / UVT 5033 TA
- Beko / 7730430204 / UVT 5033 TA

## 8. References

---

- [1]. BS EN ISO 27447:2019 Fine ceramics (advanced ceramics, advanced technical ceramics) — Test method for antibacterial activity of semiconducting photocatalytic materials
- [2]. BS ISO 18061:2014 Fine ceramics (advanced ceramics, advanced technical ceramics) — Determination of antiviral activity of semiconducting photocatalytic materials — Test method using bacteriophage Q-beta



"This report is provided on a confidential basis for the benefit of airmid healthgroup's client pursuant to the agreement between airmid healthgroup and its client. A right of action arising under this report cannot be assigned. airmid healthgroup's responsibility under this report is limited to proven negligence and will in no case be more than the testing fees. The results shown on this test report refer only to the sample(s) tested unless otherwise stated, under the conditions agreed upon. Anyone relying on this report should understand all of the details of the engagement. Only the client is authorised to publish, copy or make this report available to any third party, and then only in its entirety. This report or the airmid healthgroup limited name or logo cannot be included in any materials, including any legal, publicity or advertising activities relating to the tested product or service without the explicit written consent of airmid healthgroup Ltd."

**Report written by:**

Priyadarshini	Clara O'Brien
Scientific Officer	Scientific Officer

**Report reviewed by:**

**Vivienne  
Mahon**

Digitally signed by Vivienne Mahon  
DN: cn=Vivienne Mahon, gr=Vivienne  
Mahon, c=Ireland, h=IE, o=airmid  
healthgroup limited, ou=Science  
e=vmahon@airmidhealthgroup.com  
Reason: I am approving this  
document  
Location:  
Date: 2021-01-21 11:38Z

Vivienne Mahon

Chief Scientist/Quality Director

**\*\*\*End of Report\*\*\***